Ratings by Bernstein SocGen Group (Jeffrey Walch)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/22/2026 | Summit Therapeutics plc | SMMT | Maintain | Underperform (N/A) |
|
Details | ||
| 6/10/2026 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/9/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/5/2026 | BioNTech | BNTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/4/2026 | Nuvalent | NUVL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Underperform (N/A) |
|
Details | ||
| 5/26/2026 | Summit Therapeutics plc | SMMT | Maintain | Underperform (N/A) |
|
Details | ||
| 5/21/2026 | Incyte | INCY | New Coverage | Market Perform (N/A) |
97.08 (105.00) |
8.16% | Details | |
| 5/21/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Market Perform (N/A) |
239.01 (227.99) |
-4.61% | Details | |
| 5/21/2026 | Revolution | RVMD | New Coverage | Market Perform (N/A) |
150.33 (168.14) |
11.85% | Details | |
| 5/21/2026 | BioNTech | BNTX | New Coverage | Market Perform (N/A) |
90.36 (90.79) |
0.48% | Details | |
| 5/21/2026 | Summit Therapeutics plc | SMMT | New Coverage | Underperform (N/A) |
17.89 (14.51) |
-18.89% | Details | |
| 5/21/2026 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
154.67 (162.53) |
5.08% | Details | |
| 5/21/2026 | Nuvalent | NUVL | New Coverage | Outperform (N/A) |
102.32 (123.44) |
20.64% | Details |
